Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis

References

• Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713–1725.
   PubMed Web of Science ®Google Scholar
• Dassopoulos T, Cohen RD, Scherl EJ. Ulcerative colitis care pathway. Gastroenterology. 2015;149:238–245.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohns Colitis. 2007;1:10–20.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11:769–784.
   PubMed Web of Science ®Google Scholar
• Dignass A, Siegmund B. Joint opinion of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to vedolizumab-benefit assessment according to § 35a SGB V the G-BA. Z Gastroenterol. 2015;(53):54–58. [Article in German]
   PubMed Web of Science ®Google Scholar
• Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649–670.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–1338.
   PubMed Web of Science ®Google Scholar
• Cherry LN, Yunker NS, Lambert ER, et al. Vedolizumab: an alpha4beta7 integrin antagonist for ulcerative colitis and Crohn's disease. Ther Adv Chronic Dis. 2015;6:224–233.
   PubMed Web of Science ®Google Scholar
• Takeda Pharma A/S, Entyvio (vedolizumab). Summary of product characteristics. Aug 2018.
   Google Scholar
• Fedyk ER, Wyant T, Yang L-L, et al. Exclusive antagonism of the alpha4 beta7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis. 2012;18:2107–2119.
   PubMed Web of Science ®Google Scholar
• Soler D, Chapman T, Yang L-L, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330:864–875.
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683–691.
   PubMed Web of Science ®Google Scholar
• EMA. Assessment report - Humira (adalimumab) - Procedure No.: EMEA/H/C/000481/II/0082. 2012; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000481/WC500126007.pdf.
   Google Scholar
• AbbVie Deutschland GmbH & Co. KG, Humira (adalimumab). Summary of product characteristics. Jun 2018.
   Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Lazar A, et al. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology. 2014;146:110–118 e3.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780–787.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel J-F, D'Haens G, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013;37:204–213.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–265 e1-3.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Motoya S, Hanai H, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014;49:283–294.
   PubMed Web of Science ®Google Scholar
• Takeda GmbH. Dossier zur Nutzenbewertung gemäß § 35a SGB V - Vedolizumab (Entyvio®) Modul 4A Colitis ulcerosa. 2014 July 10; Available from: https://www.g-ba.de/downloads/92-975-565/2014-07-10_Modul4A_Vedolizumab.pdf.
   Google Scholar
• Allamneni C, Venkata K, Yun H, et al. Comparative effectiveness of vedolizumab vs. infliximab induction therapy in ulcerative colitis: experience of a real-world cohort at a tertiary inflammatory bowel disease center. Gastroenterol Res. 2018;11:41–45.
   PubMed Web of Science ®Google Scholar
• Cholapranee A, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45:1291–1302.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;160:704–711.
   PubMed Web of Science ®Google Scholar
• Kawalec P, Mikrut A, Łopuch S. Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis. J Gastroenterol Hepatol. 2014;29:1159–1170.
   PubMed Web of Science ®Google Scholar
• Vickers A, Ling CS, Ainsworth C, et al. P554 Comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis (UC): a systematic review and network meta-analysis. 10th Congress of ECCO 2015 Feb 18–21, Barcelona - Poster Presentation, 2015.
   Google Scholar
• Loftus EV, Colombel J-F, Feagan BG, et al. Long-term efficacy of vedolizumab for ulcerative colitis. J Crohns Colitis. 2017;11:400–411.
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Sandborn WJ, Ghosh S, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014;109:1771–1780.
   PubMed Web of Science ®Google Scholar